Tackling AMR needs concerted action to break down barriers

22 September 2016

Shutterstock_343309553

It is very welcome news that the international community through the United Nations General Assembly (UNGA) has recognised the urgent need for concerted global action around the steep rise in drug-resistant bacteria. By 2050, antimicrobial resistance (AMR) could claim an additional 10 million lives a year internationally if it continues unchecked – in fact in Europe, AMR already accounts for 25,000 deaths per year and is on the rise.

193 countries have agreed to act which is, of course, a positive step forward, but the challenge remains that no new antibiotics have come onto the market for 25 years. The financial rewards for creating new antibiotics are low in comparison with other more profitable drugs and there are only a few players with significant research and development projects in the pipeline.

There has been some work to try and make headway but solutions so far have often overburdened either government or the pharma sector. What is actually needed is a collaboration across the industry as well as between the public and private sectors. And it has to be based on shared risk with an agreed strategy to improve patient outcomes focussing on rewarding results rather than volume.

We have success models from other industries that we can point to and learn from. The key issue is to delink revenue from volume. The insurance sector, for example, has developed innovative risk sharing approaches to manage the impact of flooding and utilities have effective commercial mechanisms to incentivise capacity. In terms of funding R&D there are incentive models to stimulate research in vaccines and dementia that could lead the way.

It’s great to see the UN leading the charge and the key role that the UK has played in early recognition of the issue. In the UK we must roll up our collective sleeves and breakdown scientific commercial and political barriers to tackle this issue. We need to take it out of the ‘too difficult’ box by combining the best of our world leading pharma, life sciences industries and the expertise within the NHS. There is a very real opportunity to make a huge difference.

Jo Pisani leads PwC’s UK pharmaceuticals and life sciences consulting team.

Jo Pisani | Pharmaceutical and Life Science Consulting Leader
Email |+44 (0)20 7804 3744

View David's profile on LinkedIn

 

Twitter
LinkedIn
Facebook
Google+

Comments

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated and will not appear until the author has approved them.